Education
About Us
Working with TipRanks
Follow Us
Ligand Pharma (LGND)
NASDAQ:LGND
LGND Stock Chart & Stats
Day’s Range― - ―
52-Week Range$69.51 - $129.90
Previous CloseN/A
Volume21.09K
Average Volume (3M)126.16K
Market Cap
$2.08B
Enterprise Value$1.78B
Total Cash (Recent Filing)$4.04M
Total Debt (Recent Filing)$38.91M
Price to Earnings (P/E)48.0
Beta1.19
Next Earnings
May 08, 2025EPS Estimate
1.21Last Dividend Ex-Date
Nov 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding19,255,354
10 Day Avg. Volume98,761
30 Day Avg. Volume126,155
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)N/A
Price to Sales (P/S)12.46
Price to Cash Flow (P/CF)18.30
P/FCF Ratio18.50
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.43
Enterprise Value/Ebitda-25.82
Forecast
1Y Price Target
$148.67Price Target Upside37.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Ligand Pharma News
PremiumCompany Announcements
Ligand Pharma Announces Merger to Enhance ZELSUVMI Sales
PremiumCompany Announcements
Ligand Pharmaceuticals’ Earnings Call Highlights Strong Growth
PremiumCompany Announcements
Ligand Pharmaceuticals Reports Strong 2024 Financial Growth
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLigand reported positive financial results for their 4Q24, including revenues of $42.8 million, up from $28.1 million one year ago, and adjusted earnings per share of $1.27 compared with $1.05 in 4Q23.
Future Growth ProspectsLooking ahead, Ligand investors can anticipate growing royalties from Travere as Filspari gains market share in IgAN and potentially launches for FSGS, from Verona as it expands adoption of Ohtuvayre thanks to a new J-1 reimbursement code for COPD and pursues additional indications, and from Merck as it launches pneumococcal vaccine Capvaxive in Europe after approval in that jurisdiction.
Strategic PartnershipsLGND uniquely positions itself as a strategic partner, providing not just royalty capital for products in development but serving as a technology partner and biopharma incubator for innovative treatments.
Bears Say
Revenue VolatilityThere is a long-term theme of choppiness in Captisol sales and contract revenue based on the timing of orders and milestone payments.
---
Ownership Overview
2.70% Insiders
38.16% Mutual Funds
3.91% Other Institutional Investors
28.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LGND FAQ
What was Ligand Pharma’s price range in the past 12 months?
Ligand Pharma lowest stock price was $69.51 and its highest was $129.90 in the past 12 months.
What is Ligand Pharma’s market cap?
Ligand Pharma’s market cap is $2.08B.
When is Ligand Pharma’s upcoming earnings report date?
Ligand Pharma’s upcoming earnings report date is May 08, 2025 which is in 11 days.
How were Ligand Pharma’s earnings last quarter?
Ligand Pharma released its earnings results on Feb 27, 2025. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.08.
Is Ligand Pharma overvalued?
According to Wall Street analysts Ligand Pharma’s price is currently Undervalued.
Does Ligand Pharma pay dividends?
Ligand Pharma pays a Notavailable dividend of $30.012 which represents an annual dividend yield of N/A. See more information on Ligand Pharma dividends here
What is Ligand Pharma’s EPS estimate?
Ligand Pharma’s EPS estimate is 1.21.
How many shares outstanding does Ligand Pharma have?
Ligand Pharma has 19,255,354 shares outstanding.
What happened to Ligand Pharma’s price movement after its last earnings report?
Ligand Pharma reported an EPS of $1.27 in its last earnings report, beating expectations of $1.19. Following the earnings report the stock price went up 0.574%.
Which hedge fund is a major shareholder of Ligand Pharma?
Currently, no hedge funds are holding shares in LGND
---
Ligand Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$148.67 (37.57% Upside)
$148.67 (37.57% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 109.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $575.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.57%
12-Months-Change
Fundamentals
Return on Equity
-0.53%
Trailing 12-Months
Asset Growth
19.63%
Trailing 12-Months
Company Description
Ligand Pharma
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
---
LGND Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call demonstrated strong financial growth and strategic achievements, highlighted by significant increases in revenue and successful product launches. Despite some financial setbacks related to non-cash impairments and increased operating expenses, Ligand's robust financial position and promising investment pipeline indicate a positive outlook.Read More>---
LGND Stock 12 Month Forecast
Average Price Target
$148.67
▲(37.57% Upside)
Technical Analysis
Mirum Pharmaceuticals
―
Tarsus Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Biohaven Ltd.
―
Apogee Therapeutics
―
Best Analysts Covering LGND
1 Year
1 Year Success Rate
17/32 ratings generated profit
1 Year Average Return
+9.21%
reiterated a buy rating 11 days ago
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 53.13% of your transactions generating a profit, with an average return of +9.21% per trade.
---